Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.77 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518293 | 0.94 | GRM5 (0.68) | GRM5BCL6CNR1CNR2 | |
| SCHEMBL4519033 | 0.92 | GRM5 (0.64) | GRM5BCL6TNFMAPTMAPK13 | |
| SCHEMBL4508247 | 0.87 | GRM5 (1.00) | GRM5BCL6MAPT | |
| SCHEMBL4517945 | 0.86 | GRM5 (0.75) | GRM5BCL6TNFMAPTMAPK13 | |
| SCHEMBL4519571 | 0.85 | GRM5 (0.80) | GRM5BCL6MAPT | |
| SCHEMBL4523983 | 0.80 | GRM5 (0.71) | GRM5BCL6TNF | |
| SCHEMBL4518707 | 0.80 | GRM5 (0.71) | GRM5BCL6 | |
| SCHEMBL4512883 | 0.78 | GRM5 (0.83) | GRM5BCL6MAPT | |
| SCHEMBL4530571 | 0.77 | GRM5 (0.67) | GRM5BCL6MAPT | |
| SCHEMBL4502545 | 0.77 | GRM5 (1.00) | GRM5BCL6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| EP-2004624-A1 | NOVEL BI-ARYL AMINES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NAT1, MAOB, CYP2B6 | GRM5 3095/4885BCL6 2305/4885TNF 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.